However, the limited experimental design and paucity of strong data ask for more experiments to proof the feasibility of this combination for treating HCC.
1) The authors demonstrate the efficacy of TTFields in vivo even when used as monotherapy. As shown in the Figure 4 C and D, TTFields were found less effective in terms of reducing the tumors volume and weight when compared with sorafenib. However, no differences in expression of LC3 marker were observed between these groups (treated with TTFields or with sorafenib)(as shown in Figure 4D). Similarly, low evidence of apoptosis (expression of cleaved PARP) was found in these groups, as shown in Figure 4F. What is the mechanism illustrating higher efficiency of sorafenib against HCC?